YARW earnings analysis
What we found in YARW's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The filing describes a post-Merger clinical-stage biotechnology company centered on YB-101, with no approved products, no completed clinical trials, and a reported EPS loss of $2.14. Cash of $22.9 million is expected to fund operations into 2028, but the company acknowledges that substantial additional capital will be required and that failure to obtain it could raise going-concern doubt. The July 2026 trial initiation and May 2026 Fast Track designation are constructive milestones, but the ending of Finacea royalty revenue after December 31, 2026 and significant clinical, manufacturing and financing risks outweigh them.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Cash runway extends into 2028
- As of June 30, 2026, the company had $22.9 million of cash and cash equivalents. After giving effect to the Merger, management expects this cash to fund operating expenses and capital expenditure requirements into 2028.
- Post-merger strategic reset
- The Merger was completed on July 27, 2026, and the pre-Merger Yarrow business became the company’s primary business. Management states that VYNE’s historical operating results are not indicative of future results.
- YB-101 trial initiated
- YB-101’s combined Phase 2a/Phase 2b trial in adult patients with Graves’ disease was initiated in July 2026, representing the company’s principal development milestone.
- FDA Fast Track designation
- YB-101 received FDA Fast Track designation on May 20, 2026, following submission of the designation application in March 2026.
- Large accumulated deficit
- The company reported an accumulated deficit of $764.2 million as of June 30, 2026, reflecting its long history of operating losses and need for external financing.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Future financing remains necessary
- The company states it will require substantial additional funding and that failure to raise capital could raise substantial doubt about its ability to continue as a going concern. Although the $22.9 million cash balance is expected to fund operations into 2028, management still expects to raise additional capital in the future.
- Early clinical-stage concentration
- The company has not completed any clinical trials, has no products approved for commercial sale, and is substantially dependent on its sole product candidate, YB-101. The first combined Phase 2a/Phase 2b trial only began in July 2026, creating substantial development and regulatory risk.
- Finacea royalty revenue ending
- LEO Pharma notified the company that it will terminate the Finacea license agreement effective December 31, 2026. The company does not expect to recognize royalty revenue after that date, further reducing prospects for near-term revenue.
- GenSci and China supply-chain exposure
- The company currently relies solely on GenSci for biological development and manufacturing services. In addition, pharmaceutical tariffs of up to 100% on certain covered imports were authorized to begin July 31, 2026, while the BIOSECURE Act was enacted on December 18, 2025, potentially increasing supply-chain costs and causing delays.
- Material post-merger integration risk
- The post-Merger risk factors expressly supersede and replace the risk factors in the December 31, 2025 Annual Report. The company has limited experience as a combined company and warns that integration may take longer or cost more than expected and divert management attention from YB-101.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-2.14
What they said about what is next.
No numeric revenue or EPS guidance was provided in the extracted 10-Q. Management states that, after the July 27, 2026 Merger, existing cash is expected to fund operating expenses and capital expenditures into 2028, but additional capital will be required thereafter.
The filing reads worse than the one before it.
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing YARW makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever